<DOC>
	<DOCNO>NCT02189603</DOCNO>
	<brief_summary>The purpose study determine safety immunogenicity recombinant hepatitis E vaccine people older 65 year , evaluate efficacy hepatitis E vaccine population .</brief_summary>
	<brief_title>Phase Ⅳ Clinical Trial Recombinant Hepatitis E Vaccine（Hecolin®）</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis E</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy people age 16 year old time first vaccination , normal intelligence agree sign inform consent form . Healthy subject establish medical history historyoriented clinical examination enter study . Subjects reside study region next 7 month . Free history hepatitis E. Can comply request study . Axillary temperature 37 degree centigrade . For dose 1 : receiving vaccine immunoglobulin within two week ; Having serious allergic history vaccine medicine Eclampsia , epilepsy , encephalopathy history mental disease family ; Thrombocytopenia disturbance blood coagulation would lead muscle injection taboo ; Fixed suspect deficiency immunologic function , contain immunosuppressant treatment , genetic defect , HIV factor ; Congenital malformation , eccyliosis severe chronic disease ; Fixed suspect disease include fever , active infection , liver kidney disease , angiocardiopathy , malignancy , acute chronic disease ; join clinical study undergoing ; woman pregnant lactation . For dose 2 3 : Severe allergy dose 1 2 ; Severe adverse reaction associate last vaccination ; New occurrence symptom meet dose 1 exclusion criterion first dose .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>hepatitis E</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>vaccine</keyword>
	<keyword>safety</keyword>
</DOC>